HHS' decision to abruptly restrict the Food and Drug Administration's ability to require premarket review of laboratory-developed tests (LDTs) through guidance and other informal communications has industry players scrambling to figure out how this impacts their diagnostic regulatory strategies.
from Labs scramble after FDA loosens regulations on some tests
https://ift.tt/2YTpQeu
https://ift.tt/eA8V8J
No comments:
Post a Comment